ClinicalTrials.gg
CompletedNCT05075824CROSSWALK-cUpdated Apr 30, 2026

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

A Phase 2 interventional study of Crovalimab and Placebo in Sickle Cell Disease, sponsored by Hoffmann-La Roche. Completed at 27 sites in 11 countries. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Anemia, Sickle Cell with a site in Brazil — 7 open to participants now, 9 under way, 6 of them phase 3. Anemia, Sickle Cell · Brazil.

Enrollment
20th of 32
95 · median 146
Started
2022
with 6 others
Phase 2
7 of 34
none open now
Registered
25th of 34
by date
Lead sponsor
2 of 34
Hoffmann-La Roche

Among the 34 studies in Anemia, Sickle Cell with a site in Brazil, this one is the 20th largest by enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2022, is one of 7 in phase 2, and was the 25th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

7 of the 34 studies in Anemia, Sickle Cell with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Anemia, Sickle Cell with a site in Brazil, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Vaso-occlusive episodes
  • Pain crisis
04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >=40 kg.
  • Male or female with confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia) or HbSβ0 (SCD genotype of sickle cell beta zero thalassemia).
  • Two or more (>=2) to \<=10 documented VOEs in the 12 months prior to randomisation.
  • If receiving concurrent SCD-directed therapy, the participant must have been on a stable dose for a minimum of 3 months prior to study enrollment. There should be no plans to modify the participants' dosing throughout the study duration, other than for safety reasons.
  • If receiving erythropoietin, the participant must have been prescribed this medication for the preceding 3 months and be dose-stabilised for at least 3 months prior to study enrollment.
  • Vaccination against N. meningitides serotypes A, C, W, and Y and Vaccinations against H. influenza type B and S. pneumonia.
  • Participants who have been vaccinated (partially or in full) against SARS-CoV-2 with a locally approved vaccine are eligible to be enrolled in the study, 3 days or longer after inoculation.
  • Adequate hepatic and renal function.
  • For women of : agreement to remain abstinent or use during the treatment period and for 10.5 months after the final dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of hematopoietic stem cell transplant.
  • Participating in a chronic transfusion program and/or planning on undergoing an exchange transfusion during the duration of the study.
  • History of , allergic, or anaphylactic reactions to any ingredient contained in the study treatment.
  • Received active treatment on another trial within 28 days (or within five half-lives of that agent, whichever is greater) prior to screening visit, or plans to participate in another investigational drug trial.
  • \<6 g/dL.
  • Known or suspected hereditary complement deficiency.
  • Active systemic bacterial, viral, or fungal infection within 14 days before first drug administration.
  • Presence of fever (>=38 degrees Celsius) within 7 days before the first drug administration.
  • Immunised with a within 1 month before first drug administration.
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 10.5 months after the final dose of study treatment.
  • Known infection with documented \<200 cells/microliter within 24 weeks prior to screening.
  • History of N. meningitidis infection within the prior 6 months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Crovalimab

    Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.

    Drug: Crovalimab

  • Placebo comparator
    Placebo

    Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.

    Drug: Placebo

Interventions

  • Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.

  • DrugPlacebo

    Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.

06

What researchers measure

Primary outcomes

  1. Annualized rate of medical facility VOEs (AVR)

    Time frame: Baseline up to Week 49

Secondary outcomes

  1. Annualized rate of home VOE

    Time frame: Baseline up to Week 49

  2. Annualized rate of uncomplicated medical facility VOE

    Time frame: Baseline up to Week 49

  3. Annualized rate of Acute Chest Syndrome (ACS)

    Time frame: Baseline to up Week 49

  4. Annualized rate of days hospitalized for medical facility VOE

    Time frame: Baseline up to Week 49

  5. Annualized rate of days hospitalized for treatment of non-VOE complications of SCD

    Time frame: Baseline up to Week 49

  6. Time to first medical facility VOE from randomization

    Time frame: Baseline up to Week 49

  7. Change in urinary albumin-creatinine ratio

    Time frame: Baseline up to Week 49

  8. Change in Tricuspid Regurgitant Jet Velocity (TRV)

    Time frame: Baseline up to Week 49

  9. Percentage of Participants with TRV >2.5 m/s

    Time frame: Week 49

  10. Change in Patient-Reported Outcomes Measurement Information System (PROMIS)-Fatigue Score in Adults

    Time frame: Baseline up to Week 49

  11. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to 91 weeks

  12. Serum Concentrations of Crovalimab over time

    Time frame: Baseline up to Week 49

  13. Percentage of Participants with Anti-Drug Antibodies to Crovalimab

    Time frame: Baseline up to Week 49

07

Study locations

27 sites
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Mississippi Center for Advanced Medicine
    Madison, Mississippi 39110, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Hospital Sao Rafael - HSR
    Salvador, Estado de Bahia 41253-190, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, Rio Grande do Sul, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, São Paulo 18618-970, Brazil
  • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Beneficencia Portuguesa de Sao Paulo
    São Paulo, São Paulo 01323-900, Brazil
  • HEMORIO
    Rio de Janeiro, 20211-030, Brazil
  • Hospital Samaritano
    São Paulo, 01232-010, Brazil
  • CHU Henri Mondor
    Créteil, 64010, France
  • Università degli Studi della Campania Luigi Vanvitelli
    Naples, Campania 80138, Italy
  • Azienda Ospedaliera di Verona-Policlinico G.B. Rossi
    Verona, Veneto 37134, Italy
  • International Cancer Institute (ICI)
    Eldoret, 30100, Kenya
  • Gertrude's Children Hospital
    Nairobi, Kenya
  • Hopital Nini
    Tripoli, Lebanon
  • Amsterdam UMC Location VUMC
    Amsterdam, 1081 HV, Netherlands
  • Charlotte Maxeke Johannesburg Hospital
    Johannesburg, 2193, South Africa
  • Hospital General Univ. Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Adana Acibadem Hospital; Pediatric Hematology
    Adana, 01130, Turkey (Türkiye)
  • Cukurova University Medical Faculty Balcali Hospital
    Adana, 1330, Turkey (Türkiye)
  • Mersin Universitesi Tip Fakultesi Hastanesi
    Mersin, 33343, Turkey (Türkiye)
  • Central Middlesex Hospital
    London, NW10 7NS, United Kingdom
  • Hammersmith Hospital
    London, W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jun 2025, 39 months.

Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 39 months is above that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Oct 13, 2021
StartActual
Mar 9, 2022
Primary completionActual
Jun 11, 2025
CompletionActual
Apr 9, 2026
Results delay requested
Apr 24, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05075824
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 13, 2021
Start date
Mar 9, 2022
Primary completion
Jun 11, 2025
Completion
Apr 9, 2026
Last update
Apr 30, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crovalimab

Start the discussion